会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Lipid vesicles bearing carbohydrate surfaces as lymphatic directed
vehicles for therapeutic and diagnostic substances
    • 含有碳水化合物表面的脂质囊泡作为治疗和诊断物质的淋巴导向载体
    • US4310505A
    • 1982-01-12
    • US92342
    • 1979-11-08
    • John D. BaldeschwielerRonald C. GambleMarcia R. MaukTsung-Ying ShenMitree M. Ponpipom
    • John D. BaldeschwielerRonald C. GambleMarcia R. MaukTsung-Ying ShenMitree M. Ponpipom
    • A61K51/00A61K9/127A61K47/00A61K49/00A61K43/00B01J13/00
    • A61K9/1272A61K9/127A61K9/1271Y10T428/2984
    • Lipid vesicles comprising a lipid bilayer which includes analogs of cell-surface receptors such as dicetyl phosphate; stearylamine; 6-(5-cholesten-3.beta.-yloxy) hexyl 1-thio-.beta.-L-fucopyranoside; 6-(5-cholesten-3.beta.-yloxy) hexyl 1-thio-.beta.-D-galactopyranoside; 6-(5-cholesten-3.beta.-yloxy)hexyl 1-thio-.alpha.-D-mannopyranoside; 6-(5-cholesten-3-yloxy)hexyl 2-acetamido-2-deoxy-1-thio-.beta.-D-galactopyranoside; 6-(5-cholesten-3.beta.-yloxy)hexyl 6-amino-6-deoxy-1-thio-.beta.-D-galactopyranoside; or 6-(5-cholesten-3.beta.-yloxy)hexyl 6-amino-6-deoxy-1-thio-.alpha.-D-mannopyranoside; cholesterol and distearoyl phospatidylcholine, and an effective amount of physiologically compatible radioactive tracer, cytotoxic or therapeutic agent as a part of the vesicles. The vesicles of this invention can be administered to the human host and have been found to release the contents of the vesicles in a predetermined manner, i.e., controlled release, and in some cases, to be rapidly concentrated in the lymphatic system and/or liver, lungs or spleen of the host.
    • 包含脂质双层的脂质囊泡,其包括细胞表面受体的类似物,例如磷酸二鲸蜡酯; 硬脂胺 6-(5-胆甾烯-3β-氧代)己基1-硫代-β-L-吡喃葡萄糖苷; 6-(5-胆甾烯-3β-氧基)己基1-硫代-β-D-吡喃半乳糖苷; 6-(5-胆甾烯-3β-氧基)己基1-硫代-α-D-吡喃甘露糖苷; 6-(5-胆甾烯-3-基氧基)己基2-乙酰氨基-2-脱氧-1-硫代-β-D-吡喃半乳糖苷; 6-(5-胆甾烯-3β-氧基)己基6-氨基-6-脱氧-1-硫代-β-D-吡喃半乳糖苷; 或6-(5-胆甾烯-3β-氧基)己基6-氨基-6-脱氧-1-硫代-α-D-吡喃甘露糖苷; 胆固醇和二硬脂酰磷脂酰胆碱,以及有效量的生理相容的放射性示踪剂,细胞毒性剂或治疗剂作为囊泡的一部分。 本发明的囊泡可以施用于人宿主,并且已经被发现以预定的方式(即控制释放)释放囊泡的内容物,并且在一些情况下快速浓缩在淋巴系统和/或肝脏中 ,肺或脾脏的主机。
    • 7. 发明申请
    • SYSTEMS AND METHODS FOR MANAGING UTILITY CONSUMPTION
    • 用于管理实用消费的系统和方法
    • US20110178610A1
    • 2011-07-21
    • US13120920
    • 2009-10-15
    • Stephen D. O'ConnorRonald C. GambleRichard A. Suchter
    • Stephen D. O'ConnorRonald C. GambleRichard A. Suchter
    • G05B13/04G06G7/48
    • G06Q10/06
    • A system and method for monitoring and managing utility consumption includes use of (A) one or more sensors arranged to monitor an operating condition and/or utility consumption of at least one segment or appliance of a first facility; (B) a memory including at least one of (i) stored utility consumption information correlated or normalized to at least one designated parameter affecting utility consumption or (ii) hypothetical utility consumption; (C) a processor to compare the monitored information with the stored information, and (D) an output medium to store and/or display the comparison information. Stored consumption information may relate to the first facility or a second facility. Hypothetical utility consumption information may relate to a segment or appliance of the first facility operated according to optimized conditions, or an upgraded segment or appliance.
    • 一种用于监测和管理公用事业消耗的系统和方法包括使用(A)布置成监测第一设施的至少一个段或设备的运行状况和/或公用事业消耗的一个或多个传感器; (B)存储器,其包括以下至少一个:(i)存储的与至少一个影响公用事业消耗的指定参数相关或归一化的公用消费信息;(ii)假设的公用事业消费; (C)处理器,用于将所监视的信息与存储的信息进行比较,以及(D)存储和/或显示比较信息的输出介质。 存储的消费信息可能与第一设施或第二设施有关。 假设效用消耗信息可以涉及根据优化条件操作的第一设施的段或设备,或升级的段或设备。